Oral immunotherapy for peanut allergy safe for preschoolers
About 90 percent of children in an early trial for oral immunotherapy against peanut allergy safely made it to the maintenance phase of treatment, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2019 Category: Consumer Health News Source Type: news

Does Neoadjuvant pCR in Melanoma Predict Better Outcomes? Does Neoadjuvant pCR in Melanoma Predict Better Outcomes?
Jeffrey Weber discusses recent trials investigating neoadjuvant combination immunotherapy in patients with melanoma.Medscape Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 16, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Commentary Source Type: news

Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study. (Source: The Scientist)
Source: The Scientist - April 16, 2019 Category: Science Tags: News & Opinion Source Type: news

Three studies show how tumors hijack the immune system to resist radiation therapy
(University of Colorado Anschutz Medical Campus) Treg cells turn off the immune system. Three recent studies show that targeting tregs may increase the effectiveness of anti-cancer immunotherapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2019 Category: Cancer & Oncology Source Type: news

Exclusive: Philadelphia startup breaks new ground against cancer that killed John McCain
The company, founded by Jefferson researchers, posted positive clinical trial data from an early study testing its immunotherapy vaccine in patients with glioblastoma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 15, 2019 Category: American Health Authors: John George Source Type: news

Cancers 'change spots' to avoid immunotherapy
(Institute of Cancer Research) Cancers can make themselves harder for new immunotherapies to see by 'changing their spots' -- and switching off a key molecule on the surface of cells that is otherwise recognised by treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2019 Category: Cancer & Oncology Source Type: news

Medicare Aims to Expand Coverage of Cancer Care. But Is It Enough?
Doctors and patients are pushing the Trump administration to pay for a powerful but costly cancer treatment known as CAR-T, one of many new “ personalized medicines. ” (Source: NYT Health)
Source: NYT Health - April 13, 2019 Category: Consumer Health News Authors: ROBERT PEAR Tags: Health Insurance and Managed Care Drugs (Pharmaceuticals) Medicare Immunotherapy Cancer Centers for Medicare and Medicaid Services Hospitals Source Type: news

Immunotherapeutics in the Management of Metastatic Melanoma Immunotherapeutics in the Management of Metastatic Melanoma
Advances in immunotherapeutics in the last decade have drastically changed the outlook for patients with metastatic melanoma. Review the currently available immunotherapies in this update.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

More Biomarkers Needed in Cancer Immunotherapy More Biomarkers Needed in Cancer Immunotherapy
PD-L1 has proven to be a helpful but limited biomarker in helping clinicians choose cancer patients for immune checkpoint inhibition.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer
(European Society for Medical Oncology) Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news

Immunotherapy for neurodegeneration?
(Source: ScienceNOW)
Source: ScienceNOW - April 11, 2019 Category: Science Authors: Liu, Y., Aguzzi, A. Tags: Immunology, Medicine, Diseases perspective Source Type: news

' Immuno-Revolution' Has Oncologists'Forgetting About Chemo'' Immuno-Revolution' Has Oncologists'Forgetting About Chemo '
Chemotherapy still plays a major role in oncology, even in diseases revolutionized by immunotherapy; however, oncologists are becoming less and less familiar with prescribing it, argues Ravi Parikh.Medscape Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 10, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Commentary Source Type: news

OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Company Published White Paper titled, "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)" White Paper Unveils Ability to Directly Deliver Plasmid-Based IL-12 to Pancreatic, Liver a... Biopharmaceuticals, Oncology, Drug Delivery OncoSec Medical, Visceral Lesion Applicator, intratumoral, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 10, 2019 Category: Pharmaceuticals Source Type: news

Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
MARLBOROUGH, Mass., April 10, 2019 -- (Healthcare Sales & Marketing Network) -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi... Biopharmaceuticals, Oncology, Personnel Phio Pharmaceuticals, immuno-oncology, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 10, 2019 Category: Pharmaceuticals Source Type: news

Society for Immunotherapy of Cancer Publishes First-of-its-Kind...
MILWAUKEE – Today, the Society for Immunotherapy of Cancer (SITC) is pleased to announce publication of SITC’s Guide to Managing Immunotherapy Toxicity, a first-of-its-kind practical reference guide...(PRWeb April 10, 2019)Read the full story at https://www.prweb.com/releases/society_for_immunotherapy_of_cancer_publishes_first_of_its_kind_handbook_for_management_of_side_effects_associated_with_cancer_immunotherapies/prweb16233241.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 10, 2019 Category: Pharmaceuticals Source Type: news

Single-cell sequencing reveals landscape of immune cell subtypes in lung cancer tumors
(Harvard Medical School) Single-cell sequencing reveals 25 subpopulations of myeloid cells, a poorly understood family of immune cells, in lung cancer tumors. Many subpopulations are similar across humans and mice, supporting the use of mouse models in immunotherapy research. Findings set stage to assess myeloid cells as targets for new or improved immunotherapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2019 Category: International Medicine & Public Health Source Type: news

SWOG cancer research network study opens window into immune microenviroment
(SWOG) The first comprehensive study of immune cell types in pre- and post-chemotherapy cancer tissues points up a host of targets for new or existing cancer drugs that could improve patients' sensitivity to both chemotherapy and immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2019 Category: Cancer & Oncology Source Type: news

Studies give new insights on immunotherapy in elderly patients with advanced NSCLC
(European Society for Medical Oncology) Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC), where information has previously been lacking despite being the age group most commonly affected. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2019 Category: Cancer & Oncology Source Type: news

Immune-therapy could combat cancer
Injections into tumours could turn them into 'cancer vaccine factories' Related items fromOnMedica Patient's sex might affect immunotherapy outcomes Cancer survival rates not improved much in a decade Cancer survivors more prone to stress than others Free prescriptions for cancer patients Cancer cases in older people set to surge (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 9, 2019 Category: UK Health Source Type: news

Gene Therapy Trial for Mesothelioma Opens Internationally
A long-awaited phase III clinical trial of a novel gene therapy could change malignant pleural mesothelioma treatment in the future. The trial, which will include almost 50 locations around the world, opens this month for mesothelioma patients whose standard treatment has stopped working. The gene therapy drug, called TR002, is also a form of immunotherapy. It will be used in combination with gemcitabine chemotherapy in a second-line setting. “We can’t predict what the outcome will be, but we’re very excited about the potential of this treatment, and the fact there may be another drug in the armamentarium...
Source: Asbestos and Mesothelioma News - April 8, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Varian leads $54m Series C for HistoSonics
HistoSonics said today that it closed a $54 million Series C round led by Varian Medical (NYSE:VAR) that included a contribution from Johnson & Johnson (NYSE:JNJ). The Ann Arbor, Mich.-based company, which is developing an image-guided, robotically assisted platform using non-invasive and non-thermal technologies, said Lumira Ventures, Venture Investors, the State of Wisconsin Investment Board and existing backers also participated – including robot-assisted surgery pioneer Dr. Fred Moll. HistoSonics said it plans to use the proceeds to complete “key regulatory and commercial milestones” and expa...
Source: Mass Device - April 8, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Robotics Wall Street Beat HistoSonics Inc. johnsonandjohnson Varian Medical Systems Source Type: news

Immune cells fighting blood cancer visualized for the first time
When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) represent a promising immunotherapy strategy, developed with the aim of tackling tumors head-on. But the occurrence of relapse in some patients remains a challenge. (Source: World Pharma News)
Source: World Pharma News - April 8, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Immune cells fighting blood cancer visualized for the first time
(Institut Pasteur) When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) represent a promising immunotherapy strategy, developed with the aim of tackling tumors head-on. But the occurrence of relapse in some patients remains a challenge. Scientists at the Institut Pasteur have identified the precise function of CAR T cells in a bid to optimize future therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2019 Category: International Medicine & Public Health Source Type: news

City of Hope scientists are using combination immunotherapy to treat advanced cancers
(City of Hope) City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission. Daneng Li, M.D., is treating patients with advanced liver (hepatocellular) cancer, while Joseph Chao, M.D., is treating patients with advanced stomach and esophageal cancer (gastric and gastroesophageal junction adenocarcinoma). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2019 Category: Cancer & Oncology Source Type: news

Mount Sinai researchers develop treatment that turns tumors into cancer vaccine factories
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2019 Category: Cancer & Oncology Source Type: news

Precursor Immunotherapy to Prevent Squamous Cell Carcinoma
Researchers evaluated whether  treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Cancer ’ s Trick for Dodging the Immune System
In a study of tumors in mice, scientists may have learned why immunotherapy doesn ’ t work in many patients and what might be done to boost its effectiveness. (Source: NYT Health)
Source: NYT Health - April 4, 2019 Category: Consumer Health News Authors: MATT RICHTEL Tags: Immune System Mice Prostate Cancer Tumors Research Immunotherapy Lymph Nodes and Lymphatic System Allison, James P Cell (Journal) Source Type: news

Medical News Today: Cancer: Are probiotics making immunotherapy less effective?
Probiotic supplements could be having a detrimental effect on this particular form of cancer treatment, according to new research. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 4, 2019 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Cancer exports molecular 'saboteurs' to remotely disarm immune system
(University of California - San Francisco) Immunotherapy drugs known as checkpoint inhibitors have revolutionized cancer treatment: many patients with malignancies that until recently would have been considered untreatable are experiencing long-term remissions. Now, UC San Francisco researchers have identified a surprising phenomenon that may explain why many cancers don't respond to these drugs, and hints at new strategies to unleash the immune system against disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 4, 2019 Category: Cancer & Oncology Source Type: news

Entinostat Plus Pembrolizumab Shows Promise in Previously Treated Melanoma
Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: Ryan J. Sullivan, MD Source Type: news

Probiotics may be good for your gut but bad for your immune system, study suggests
Taking probiotics may actually make the gut microbiome less diverse, and in turn prevent immunotherapy from fighting cancer, new research from the Parker Institute suggests. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2019 Category: Consumer Health News Source Type: news

Almost Three-Quarters of Allergists Have Prescribed SLIT
WEDNESDAY, April 3, 2019 -- More than 73 percent of U.S. allergists report prescribing sublingual immunotherapy (SLIT), according to research published online April 1 in the Annals of Allergy, Asthma& Immunology. Anita Sivam, D.O., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news

Immunotherapy kicks and kills HIV by exploiting a common virus
(University of Pittsburgh) In a first on the quest to cure HIV, University of Pittsburgh scientists report that they've developed an all-in-one immunotherapy approach that not only kicks HIV out of hiding in the immune system, but also kills it. The key lies in immune cells designed to recognize an entirely different virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 3, 2019 Category: Infectious Diseases Source Type: news

Provention Bio Announces Key Additions to its Senior Management Team
Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development OLDWICK, N.J., April 2, 2019 -- (Healthcare Sales & Marketing Network) -- Provention Bio, Inc. (Nas... Biopharmaceuticals, Personnel Provention Bio, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 2, 2019 Category: Pharmaceuticals Source Type: news

Surgery Tied To 44% Increased Survival In Women With Advanced Breast Cancer
(CNN) — Surgery is tied to improved chances of survival among stage 4 breast cancer patients, a new study suggests, but who has access to surgery and who doesn’t can vary drastically, based on factors including income level and where treatment is administered. Surgery to remove tumors was associated with a 44% increased chance of survival within an average followup period of 21 months, according to the abstract, to be presented at the American Association for Cancer Research’s annual meeting in Atlanta this week. “If breast surgery is to be considered by patients and providers when deciding treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer CNN Source Type: news

Is your melanoma hot enough for immunotherapy?
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study presented at AACR 2019 shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

Hope restored: Immunotherapy a “game-changer” for mother of two with lung cancer
Jenn Bales calls them “my people.” No, they’re not her children, her boyfriend or her mother. They’re the people who were able to help restore hope in her life. The people who laughed with her, cried with her, and helped fight for her when she was at her lowest point. Her people are her doctors, nurses, advanced clinical practitioners and her entire care team at Atrium Health’s Levine Cancer Institute. And they’re the ones who helped Bales find hope when it looked like there wasn’t… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 1, 2019 Category: American Health Authors: Atrium Health Source Type: news

Topical Immunotherapy Reduces Squamous Cell Carcinoma Risk Topical Immunotherapy Reduces Squamous Cell Carcinoma Risk
A common chemotherapy combined with a synthetic vitamin D analog eliminated actinic keratosis and decreased skin cancer risk for 3 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novartis scoops up IFM immunotherapy subsidiary for $310 million
Pharmaceutical giant Novartis will pay $310 million to purchase an Atlas Venture-backed Boston startup focused on treatments using the body's immune system. Novartis (NYSE: NVS) has signed a deal to purchase pre-commercial company IFM Tre. Another $1.27 billion will be available in milestone payments, bringing the deal total to nearly $1.6 billion, according to a press release. IFM Tre launched in July 2018 with plans to develop therapies for inflam matory diseases that block the production of… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Pitt research reveals how immune cells help tumors escape body's defenses
(University of Pittsburgh) New findings from Pitt and UPMC Hillman Cancer Center researchers reveal how immune cells turn off killer T cells, pointing to new drug targets that can improve the success of cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

UC San Diego Health treats 1st cancer patient with stem-cell derived natural killer cells
(University of California - San Diego) Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 1, 2019 Category: International Medicine & Public Health Source Type: news

Tuberculosis Can Emerge After Cancer Immunotherapy
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system's antitumor response. (Source: The Scientist)
Source: The Scientist - April 1, 2019 Category: Science Tags: Notebook Magazine Issue Source Type: news

Cancer Vaxxer: A Profile of Miriam Merad
The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines. (Source: The Scientist)
Source: The Scientist - April 1, 2019 Category: Science Tags: Profile Magazine Issue Source Type: news

Contending with Resistance in Cancer Immunotherapy
Researchers describe ways to study how cancer cells evade therapies that harness the immune system. (Source: The Scientist)
Source: The Scientist - April 1, 2019 Category: Science Tags: Lab Tools Magazine Issue Source Type: news

New immnotherapy can shrink otherwise untreatable breast, lung and mesothelioma tumors
Researchers at Memorial Sloan Kettering have deveoped the world's first immunotherapy that can shrink treatment-resistant lung, breast and mesothelioma tumors in some two million patients. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2019 Category: Consumer Health News Source Type: news

Immunotherapy combination effective for patients with rare neuroendocrine cancer
(SWOG) A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news

CD40 combination therapy can shrink pancreatic tumors
(University of Pennsylvania School of Medicine) A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news

Major step towards individual cancer immunotherapy
(ETH Zurich) Medicine has great hopes for personalised cancer immunotherapy. The idea is to have a vaccine prompt the immune system to fight a tumour. Scientists at ETH Zurich have developed a method that allows them to determine which molecules are suited to patient-specific immunisation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2019 Category: Cancer & Oncology Source Type: news

NCCN: New Bladder Cancer Guidelines Include Updated Staging, Immunotherapy Options
The updates to the guidelines reflect  recent advances, including recommended immunotherapies and changes in tumor staging. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2019 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news